Mirikizumab (IL23A) Antibody, Monoclonal
Code | Size | Price |
---|
PSI-10-858-0.1mg | 0.1mg | £657.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: IgG4-kappa
Antibody Clonality: Recombinant Antibody
Regulatory Status: RUO
Shipping:
blue ice
Storage:
Store at -80˚C
Images
Documents
Further Information
Additional Names:
LY-3074828
Background:
Mirikizumab is humanized IgG4 monoclonal antibody that targets p19 subunit binding to IL-23. Currently, mirikizumab is being developed for a variety of immune diseases, including psoriasis, UC, and Crohn's disease (CD), of which the treatment of moderate to severe plaque psoriasis is already in phase III clinical practice.
Buffer:
PBS buffer pH7.5
Concentration:
batch dependent
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Humanized / IL23A [Homo sapiens]
NCBI Organism:
homo sapiens
Purification:
>95%
Research Area:
Drug Analogues
Source:
CHO cells
User NOte:
Optimal dilutions for each application to be determined by the researcher.